Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C virus retreatment in decompensated cirrhosis

Sonalie Patel; Michelle T Martin; Steven L Flamm

doi:10.1111/liv.15075

Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C virus retreatment in decompensated cirrhosis

Liver Int. 2021 Dec;41(12):3024-3027. doi: 10.1111/liv.15075. Epub 2021 Oct 18.

Authors

Sonalie Patel¹, Michelle T Martin^{2

3}, Steven L Flamm⁴

Affiliations

¹ Specialty Pharmacy, Northwestern Medicine, Chicago, Illinois, USA.
² Department of Pharmacy Practice, University of Illinois at Chicago College of Pharmacy, Chicago, Illinois, USA.
³ Liver Clinic, University of Illinois Hospital and Health Sciences System, Chicago, Illinois, USA.
⁴ Department of Medicine, Northwestern Feinberg School of Medicine, Chicago, Illinois, USA.

PMID: 34592051
DOI: 10.1111/liv.15075

No abstract available

Keywords: cirrhosis; decompensated; direct-acting antivirals; hepatitis C virus; retreatment; salvage therapy; sofosbuvir; velpatasvir; voxilaprevir.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aminoisobutyric Acids
Antiviral Agents / therapeutic use
Carbamates
Cyclopropanes
Drug Therapy, Combination
Genotype
Hepacivirus / genetics
Hepatitis C, Chronic* / complications
Hepatitis C, Chronic* / drug therapy
Heterocyclic Compounds, 4 or More Rings / therapeutic use
Humans
Lactams, Macrocyclic
Leucine / analogs & derivatives
Liver Cirrhosis / drug therapy
Proline / analogs & derivatives
Quinoxalines
Retreatment
Sofosbuvir* / therapeutic use
Sulfonamides

Substances

Aminoisobutyric Acids
Antiviral Agents
Carbamates
Cyclopropanes
Heterocyclic Compounds, 4 or More Rings
Lactams, Macrocyclic
Quinoxalines
Sulfonamides
voxilaprevir
Proline
Leucine
velpatasvir
Sofosbuvir